Open AccessEfficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes
Author(s) -
Cao Ying,
Gao Fang,
Zhang Qian,
Xu Lingling,
Wan Qian,
Li Wenqi,
Li Jimin,
Wang Ling,
Xue Yaoming
Publication year - 2017
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12436
Subject(s) - medicine , sitagliptin , insulin glargine , glycemic , hypoglycemia , type 2 diabetes , insulin , insulin aspart , gastroenterology , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , endocrinology , clinical endpoint , randomized controlled trial
Background The aim of the randomized present study was to compare the therapeutic efficacy and safety of a combination of sitagliptin, a dipeptidyl peptidase (DPP)‐4 inhibitor, plus insulin glargine (GL + sita) with that of premixed insulin aspart 30 (NOV) for type 2 diabetes (T2D) patients controlled with oral hypoglycemic drugs (HbA1c 7 %–9 %). Methods Sixty‐five patients were randomized (1: 1) to the GL + sita (n = 33) and NOV (n = 32) groups and were treated with the combination regimen or premixed insulin twice a day for 16 weeks. The primary endpoint was mean change in HbA1c. Secondary endpoints included fasting blood glucose, blood glucose profiles (seven time points), rate of achieving target HbA1c (<7 % or ≤6.5 %), insulin dose, incidence of hypoglycemia, and body weight. Results After 16 weeks, there was no significant difference in HbA1c between the two groups, although more patients achieved HbA1c <7.0 % in the GL + sita group. There was a significant difference in body weight changes between the GL + sita and NOV groups (−0.45 vs 1.52 kg, respectively; P < 0.001). Mean plasma glucose and the mean amplitude of glycemic excursion were significantly lower in the GL + sita than NOV group ( P < 0.005), as was the incidence of symptomatic hypoglycemia (2.85 % vs. 13.3 %, respectively; P < 0.001). Conclusion The combination of GL + sita greatly improved HbA1c in T2D patients (HbA1c 7 %–9 %) with an efficacy that was equal to that of premixed insulin. Thus, GL + sita treatment is a viable option for patients who fail to achieve glycemic control using oral hypoglycemic drugs.